Wugen is a clinical stage immuno-oncology cell therapy company, developing off-the-shelf NK and CAR-T cell therapies for the treatment of both solid tumor and heme malignancies. Our lead program, WU-NK-101 is being tested in Phase 1b clinical trials. As the first product derived from our memory NK cell therapy platform, WU-NK-101 has shown robust efficacy (and safety) in AML patients.
The company is engaged in developing a pipeline of off-the-shelf memory natural killer (NK) cell therapies to treat a broad range of hematological and solid tumor malignancies, enabling the medical community to effectively combat life-threatening tumors.
Total Funding: $172 M
Funding Stage: Series B
Business Stage: Scaling Up
Market: B2B
Company Size: 51 to 100
Founded: 2018
Jul 2021
- Wugen Raised $172M in Series B Funding
Apr 2021
- Wugen Hired Daniel Kemp, Ph.D., as Chief Executive Officer
Mar 2021
- Wugen Partnered with Alpha Biopharma in Asia
Mar 2021
- Wugen Announced Exclusive License Agreement With HCW Biologics
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Wugen
Chief Financial Officer
St Louis, MO
Head of NK Process Development
St Louis, MO
Scientist / Engineer: CMC Technology Transfer
St Louis, MO
Associate Director/Director, Clinical Quality Assurance
San Diego, CA
